HC Wainwright & Co. Maintains Buy on CymaBay Therapeutics, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on CymaBay Therapeutics (NASDAQ:CBAY) and raises the price target from $19 to $21.
August 14, 2023 | 2:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The 'Buy' rating maintained by HC Wainwright & Co. and the raised price target could potentially boost CymaBay Therapeutics' stock in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The maintained 'Buy' rating and increased price target from HC Wainwright & Co. suggest a positive outlook for CymaBay Therapeutics, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100